LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation Francesca Pischedda1*, Maria Daniela Cirnaru2*, Luisa Ponzoni3,
![Vuelta al colegio: 62 instituciones privadas ya recibieron el aval oficial para abrir | Noticias de Buenos Aires Vuelta al colegio: 62 instituciones privadas ya recibieron el aval oficial para abrir | Noticias de Buenos Aires](https://parabuenosaires.com/wp-content/uploads/2020/10/colegio-privado1.jpg)
Vuelta al colegio: 62 instituciones privadas ya recibieron el aval oficial para abrir | Noticias de Buenos Aires
![Caecal metastasis from breast cancer presenting as intestinal obstruction | World Journal of Surgical Oncology | Full Text Caecal metastasis from breast cancer presenting as intestinal obstruction | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1477-7819-6-47/MediaObjects/12957_2007_Article_445_Fig1_HTML.jpg)
Caecal metastasis from breast cancer presenting as intestinal obstruction | World Journal of Surgical Oncology | Full Text
![Foods | Free Full-Text | Exploring the DPP-IV Inhibitory, Antioxidant and Antibacterial Potential of Ovine “Scotta” Hydrolysates | HTML Foods | Free Full-Text | Exploring the DPP-IV Inhibitory, Antioxidant and Antibacterial Potential of Ovine “Scotta” Hydrolysates | HTML](https://www.mdpi.com/foods/foods-10-03137/article_deploy/html/images/foods-10-03137-g004.png)
Foods | Free Full-Text | Exploring the DPP-IV Inhibitory, Antioxidant and Antibacterial Potential of Ovine “Scotta” Hydrolysates | HTML
CER 112 - Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer
![Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial - ScienceDirect Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589537022002103-gr3.jpg)